17Dec 2022
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial

Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial

It remains unknown whether the consistently observed increase in haematocrit with sodium-glucose cotransporter two inhibitors is caused by diuresis-associated haemoconcentration or increased erythropoiesis. The study aimed to investigate the early effect of empagliflozin on erythropoiesis and iron metabolism in patients with heart failure with reduced ejection fraction (HFrEF). These findings suggest that empagliflozin increases erythropoiesis and augments early iron utilization in patients with HFrEF. These mechanisms may contribute to the cardioprotective properties of empagliflozin.

  • #cardiology

Like

Save

Share